S&P 500 7,716.12 ▲ 39.35 (+0.51%) DOW 52,409.51 ▲ 47.93 (+0.09%) NASDAQ 26,418.24 ▲ 248.86 (+0.95%) US Markets Open â€ĸ 11:01 AM ET

VKTX

Viking Therapeutics, Inc.

Price Chart
Latest Quote

$24.81

+0.60 (+2.48%)
Current Price
Previous Close $24.21
Open $24.23
Day High $24.93
Day Low $23.82
Volume 893,682
Fetched: 2026-10-27T15:01:00
Stock Information
Shares Outstanding 127.17M
Total Debt $4.09M
Cash Equivalents $501.66M
Net Income $-534.80M
Sector Healthcare
Industry Biotechnology
Market Cap $3.15B
EPS (TTM) $-4.67
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$2.33B
Income$-534.80M
Book/sh$3.50
Cash/sh$3.94
Employees65
Financial Ratios
Quick Ratio4.58
Current Ratio4.72
Debt/Eq1.00
Returns & Margins
ROA-51.86%
ROE-88.85%
Ownership
Insider Ownership2.84%
Institutional Ownership60.41%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-5.71
P/B7.09
Analyst Data
Recommendationstrong_buy
Target Price$95.05
Technical Indicators
SMA20$27.29
SMA50$30.99
SMA200$32.49
RSI36.30
ATR1.4152
Shares Float113.73M
Short Float21.44%
Short Ratio3.66
Volatility0.65
Rel Volume0.17
Performance History
Week-7.11%
Month-24.89%
Quarter-25.79%
6 Months-23.40%
YTD-29.95%
Year-27.92%
3 Years+147.36%
5 Years+324.83%
10 Years+2176.15%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $24.81 893,682
2026-10-26 $24.21 3,555,300
2026-10-23 $24.40 4,675,300
2026-10-22 $25.83 3,525,000
2026-10-21 $26.38 3,293,400
2026-10-20 $26.71 4,649,700
2026-10-19 $25.05 3,741,100
2026-10-16 $25.17 7,582,100
2026-10-15 $27.37 5,215,600
2026-10-14 $25.47 6,581,100
2026-10-13 $26.65 5,739,200
2026-10-12 $28.34 2,861,900
2026-10-09 $28.51 4,036,200
2026-10-08 $27.73 8,732,700
2026-10-07 $28.54 5,401,700
2026-10-06 $28.38 7,109,600
2026-10-05 $29.28 6,277,400
2026-10-02 $29.94 6,367,100
2026-10-01 $30.51 6,832,000
2026-09-30 $32.60 7,000,100
2026-09-29 $31.81 8,025,800
2026-09-28 $33.03 8,575,400
About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

📰 Latest News
No news articles available at the moment. Check back later for updates on VKTX.
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $393,342,000 $150,921,000 $100,827,000 $70,355,000
Other Income Expense $55,000 $112,000 - $-42,000
Net Non Operating Interest Income Expense $33,648,000 $40,846,000 $14,932,000 $1,530,000
Total Other Finance Cost $56,000 $94,000 $88,000 $59,000
Operating Expense $393,342,000 $150,921,000 $100,827,000 $70,355,000
General And Administrative Expense $48,387,000 $49,277,000 $37,021,000 $16,121,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Net Interest Income $33,648,000 $40,846,000 $14,932,000 $1,530,000
Interest Income $33,704,000 $40,940,000 $15,020,000 $1,589,000
Normalized Income $-359,694,000 $-110,075,000 $-85,895,000 $-68,825,000
Net Income From Continuing And Discontinued Operation $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Total Operating Income As Reported $-393,342,000 $-150,921,000 $-100,827,000 $-70,355,000
Net Income Common Stockholders $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Net Income $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Net Income Including Noncontrolling Interests $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Net Income Continuous Operations $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Pretax Income $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Interest Income Non Operating $33,704,000 $40,940,000 $15,020,000 $1,589,000
Operating Income $-393,342,000 $-150,921,000 $-100,827,000 $-70,355,000
Per Share
Diluted EPS $-3.19 $-1.01 $-0.91 $-0.90
Basic EPS $-3.19 $-1.01 $-0.91 $-0.90
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-392,966,000 $-150,687,000 $-100,535,000 $-70,022,000
Total Unusual Items $55,000 $112,000 - $-42,000
Total Unusual Items Excluding Goodwill $55,000 $112,000 - $-42,000
Reconciled Depreciation $431,000 $346,000 $292,000 $291,000
EBITDA (Bullshit earnings) $-392,911,000 $-150,575,000 $-100,535,000 $-70,064,000
EBIT $-393,342,000 $-150,921,000 $-100,827,000 $-70,355,000
Diluted Average Shares $112,667,000 $109,037,000 $94,347,000 $76,834,000
Basic Average Shares $112,667,000 $109,037,000 $94,347,000 $76,834,000
Diluted NI Availto Com Stockholders $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Gain On Sale Of Security $55,000 $112,000 - $-42,000
Research And Development $344,955,000 $101,644,000 $63,806,000 $54,234,000
Selling General And Administration $48,387,000 $49,277,000 $37,021,000 $16,121,000
Other Gand A $48,387,000 $49,277,000 $37,021,000 $16,121,000
Fetched: 2026-10-13
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $639,062,000 $880,278,000 $348,419,000 $145,322,000
Total Assets $715,729,000 $908,321,000 $368,490,000 $168,529,000
Total Non Current Assets $131,000 $1,105,000 $1,265,000 $1,489,000
Non Current Prepaid Assets $46,000 $46,000 $33,000 $33,000
Non Current Deferred Assets $0 $56,000 $106,000 $38,000
Current Assets $715,598,000 $907,216,000 $367,225,000 $167,040,000
Other Current Assets $1,806,000 $1,128,000 $2,522,000 $3,411,000
Prepaid Assets $8,053,000 $3,476,000 $2,624,000 $8,144,000
Cash Cash Equivalents And Short Term Investments $705,739,000 $902,612,000 $362,079,000 $155,485,000
Cash And Cash Equivalents $165,810,000 $26,676,000 $55,516,000 $36,632,000
Debt
Total Debt $137,000 $1,119,000 $1,260,000 $1,564,000
Long Term Debt And Capital Lease Obligation $0 $630,000 $936,000 $1,260,000
Current Debt And Capital Lease Obligation $137,000 $489,000 $324,000 $304,000
Liabilities
Total Liabilities Net Minority Interest $76,667,000 $28,043,000 $20,071,000 $23,207,000
Total Non Current Liabilities Net Minority Interest $0 $630,000 $936,000 $1,260,000
Current Liabilities $76,667,000 $27,413,000 $19,135,000 $21,947,000
Payables And Accrued Expenses $76,530,000 $26,924,000 $18,811,000 $21,643,000
Payables $53,251,000 $9,813,000 $7,512,000 $8,529,000
Accounts Payable $53,251,000 $9,813,000 $7,512,000 $8,529,000
Equity
Common Stock Equity $639,062,000 $880,278,000 $348,419,000 $145,322,000
Total Equity Gross Minority Interest $639,062,000 $880,278,000 $348,419,000 $145,322,000
Stockholders Equity $639,062,000 $880,278,000 $348,419,000 $145,322,000
Gains Losses Not Affecting Retained Earnings $378,000 $-788,000 $-389,000 $-1,102,000
Other Equity Adjustments $378,000 $-788,000 $-389,000 $-1,102,000
Retained Earnings $-847,546,000 $-487,907,000 $-377,944,000 $-292,049,000
Other
Ordinary Shares Number $114,793,067 $111,573,519 $100,113,770 $78,257,258
Share Issued $114,793,067 $111,573,519 $102,307,021 $80,450,509
Tangible Book Value $639,062,000 $880,278,000 $348,419,000 $145,322,000
Invested Capital $639,062,000 $880,278,000 $348,419,000 $145,322,000
Working Capital $638,931,000 $879,803,000 $348,090,000 $145,093,000
Capital Lease Obligations $137,000 $1,119,000 $1,260,000 $1,564,000
Total Capitalization $639,062,000 $880,278,000 $348,419,000 $145,322,000
Treasury Stock $0 $0 $6,795,000 $6,795,000
Additional Paid In Capital $1,486,229,000 $1,368,972,000 $733,546,000 $445,267,000
Capital Stock $1,000 $1,000 $1,000 $1,000
Common Stock $1,000 $1,000 $1,000 $1,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $0 $630,000 $936,000 $1,260,000
Current Capital Lease Obligation $137,000 $489,000 $324,000 $304,000
Current Accrued Expenses $23,279,000 $17,111,000 $11,299,000 $13,114,000
Net PPE $85,000 $1,003,000 $1,126,000 $1,418,000
Gross PPE $85,000 $1,003,000 $1,126,000 $1,418,000
Buildings And Improvements $85,000 $1,003,000 $1,126,000 $1,418,000
Properties $0 $0 $0 $0
Other Short Term Investments $539,929,000 $875,936,000 $306,563,000 $118,853,000
Treasury Shares Number - - $2,193,251 $2,193,251
Fetched: 2026-10-13
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-278,685,000 $-87,790,000 $-73,376,000 $-48,397,000
Operating Activities
Operating Cash Flow $-278,685,000 $-87,790,000 $-73,376,000 $-48,397,000
Cash Flow From Continuing Operating Activities $-278,685,000 $-87,790,000 $-73,376,000 $-48,397,000
Operating Gains Losses $-55,000 $-112,000 - -
Investing Activities
Investing Cash Flow $341,388,000 $-553,366,000 $-179,086,000 $54,753,000
Cash Flow From Continuing Investing Activities $341,388,000 $-553,366,000 $-179,086,000 $54,753,000
Financing Activities
Issuance Of Capital Stock $0 $597,094,000 $269,760,000 -
Financing Cash Flow $76,439,000 $612,464,000 $271,376,000 $4,163,000
Cash Flow From Continuing Financing Activities $76,439,000 $612,464,000 $271,376,000 $4,163,000
Net Other Financing Charges $73,948,000 $4,557,000 $-5,152,000 $10,132,000
Net Common Stock Issuance $0 $597,094,000 $269,760,000 $-6,817,000
Common Stock Issuance $0 $597,094,000 $269,760,000 -
Repurchase Of Capital Stock - $0 $0 $-6,817,000
Other
End Cash Position $165,810,000 $26,676,000 $55,516,000 $36,632,000
Beginning Cash Position $26,676,000 $55,516,000 $36,632,000 $26,371,000
Effect Of Exchange Rate Changes $-8,000 $-148,000 $-30,000 $-258,000
Changes In Cash $139,142,000 $-28,692,000 $18,914,000 $10,519,000
Proceeds From Stock Option Exercised $2,491,000 $10,813,000 $6,768,000 $848,000
Net Investment Purchase And Sale $341,388,000 $-553,366,000 $-179,086,000 $54,753,000
Sale Of Investment $759,425,000 $560,002,000 $299,217,000 $176,184,000
Purchase Of Investment $-418,037,000 $-1,113,368,000 $-478,303,000 $-121,431,000
Change In Working Capital $48,978,000 $9,362,000 $3,548,000 $10,189,000
Change In Other Current Liabilities $-505,000 $-402,000 $-347,000 $-189,000
Change In Payables And Accrued Expense $49,606,000 $8,119,000 $-2,834,000 $12,894,000
Change In Accrued Expense $6,168,000 $5,816,000 $-1,816,000 $5,809,000
Change In Payable $43,438,000 $2,303,000 $-1,018,000 $7,085,000
Change In Account Payable $43,438,000 $2,303,000 $-1,018,000 $7,085,000
Change In Prepaid Assets $-5,199,000 $446,000 $6,408,000 $-3,130,000
Change In Receivables $5,076,000 $1,199,000 $321,000 $614,000
Other Non Cash Items $66,000 $132,000 $131,000 $100,000
Stock Based Compensation $40,818,000 $29,712,000 $16,750,000 $8,673,000
Amortization Of Securities $-9,284,000 $-17,267,000 $-8,202,000 $1,217,000
Depreciation Amortization Depletion $431,000 $346,000 $292,000 $291,000
Depreciation And Amortization $431,000 $346,000 $292,000 $291,000
Depreciation $431,000 $346,000 $292,000 $291,000
Gain Loss On Investment Securities $-55,000 $-112,000 - -
Net Income From Continuing Operations $-359,639,000 $-109,963,000 $-85,895,000 $-68,867,000
Common Stock Payments - $0 $0 $-6,817,000
Change In Interest Payable - - - $614,000
Fetched: 2026-10-13